Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PULSOV: SPARs Prognostic Value in CRVO
NCT04793100Completed
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- Mar 2021
- Primary completion
- Mar 2025
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Open-label, single-arm trial of aflibercept in central retinal vein occlusion (CRVO), sponsored by Adolphe de Rothschild Foundation Hospital. Primary endpoint: Change in visual acuity between inclusion and visit at one year at 1 year. Started Mar 2021; status: completed.
02
Drugs
aflibercept
03
Conditions
central retinal vein occlusion (CRVO)
Beyond the preview
Go deeper on NCT04793100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04793100.